Search research articles
Contact Us
Filters
Showing results (101-110 of 191) with videos related to
Page
of 20
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2024
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers
Young Kwang Chae, Lucy Corthell, Sandip Pravin Patel, et al.
JAMA
|
March 2, 2021
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial
Patrick A Brown, Lingyun Ji, Xinxin Xu, et al.
Science Translational Medicine
|
January 18, 2019
Tuberculosis following PD-1 blockade for cancer immunotherapy
Daniel L Barber, Shunsuke Sakai, Ragini R Kudchadkar, et al.
Blood Advances
|
November 2, 2022
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia
Anjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.
Journal for Immunotherapy of Cancer
|
July 3, 2021
Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data
Kerry L Reynolds, Shaily Arora, Ravikumar Komandur Elayavilli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 19, 2017
Immune Modulation Therapy and Imaging: Workshop Report
Anthony F Shields, Paula M Jacobs, Mario Sznol, et al.
JCO Clinical Cancer Informatics
|
July 24, 2019
An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer
Mark Stewart, Andrew D Norden, Nancy Dreyer, et al.
JAMA Oncology
|
November 23, 2022
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial
Joseph M Unger, Amy Darke, Megan Othus, et al.
Journal for Immunotherapy of Cancer
|
August 12, 2021
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
Michael J Wagner, Megan Othus, Sandip P Patel, et al.
NPJ Precision Oncology
|
January 24, 2025
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
Sandip P Patel, Eleanor Cano-Linson, Young Kwang Chae, et al.
Page
of 20
Search research articles
Search
Showing results (101-110 of 191) with videos related to
Sort By:
Page
of 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2024
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers
Young Kwang Chae, Lucy Corthell, Sandip Pravin Patel, et al.
JAMA
|
March 2, 2021
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial
Patrick A Brown, Lingyun Ji, Xinxin Xu, et al.
Science Translational Medicine
|
January 18, 2019
Tuberculosis following PD-1 blockade for cancer immunotherapy
Daniel L Barber, Shunsuke Sakai, Ragini R Kudchadkar, et al.
Blood Advances
|
November 2, 2022
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia
Anjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.
Journal for Immunotherapy of Cancer
|
July 3, 2021
Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data
Kerry L Reynolds, Shaily Arora, Ravikumar Komandur Elayavilli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 19, 2017
Immune Modulation Therapy and Imaging: Workshop Report
Anthony F Shields, Paula M Jacobs, Mario Sznol, et al.
JCO Clinical Cancer Informatics
|
July 24, 2019
An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer
Mark Stewart, Andrew D Norden, Nancy Dreyer, et al.
JAMA Oncology
|
November 23, 2022
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial
Joseph M Unger, Amy Darke, Megan Othus, et al.
Journal for Immunotherapy of Cancer
|
August 12, 2021
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
Michael J Wagner, Megan Othus, Sandip P Patel, et al.
NPJ Precision Oncology
|
January 24, 2025
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
Sandip P Patel, Eleanor Cano-Linson, Young Kwang Chae, et al.
Page
of 20